The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer

HER2 mutations (HER2mut) induce endocrine resistance in estrogen receptor-positive (ER+) breast cancer. In this single-arm multi-cohort phase II trial, we evaluated the efficacy of neratinib plus fulvestrant in patients with ER+/HER2mut, HER2 non-amplified metastatic breast cancer (MBC) in the fulve...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Clinical cancer research 2022-04, Vol.28 (7), p.1258-1267
Hauptverfasser:	Ma, Cynthia X, Luo, Jingqin, Freedman, Rachel A, Pluard, Timothy J, Nangia, Julie R, Lu, Janice, Valdez-Albini, Frances, Cobleigh, Melody, Jones, Jason M, Lin, Nancy U, Winer, Eric P, Marcom, P Kelly, Thomas, Shana, Anderson, Jill, Haas, Brittney, Bucheit, Leslie, Bryce, Richard, Lalani, Alshad S, Carey, Lisa A, Goetz, Matthew P, Gao, Feng, Kimmick, Gretchen, Pegram, Mark D, Ellis, Matthew J, Bose, Ron
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - adverse effects Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Female Fulvestrant Humans Quinolines Receptor, ErbB-2 - genetics Receptor, ErbB-2 - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!